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The cholinergic systemis involvedin specific behaviouralresponses and cognitive processes.Here, we examined
potential alterations in the brain levels of key cholinergic enzymes in cirrhotic patients and animal models with
liver failure. An increase (»30%) in the activity of the acetylcholine-hydrolyzing enzyme, acetylcholinesterase
(AChE) is observed in the brain cortex from patients deceased from hepatic coma, while the activity of the
acetylcholine-synthesizing enzyme, choline acetyltransferase, remains unaffected. In agreement with the
human data, AChE activity in brain cortical extracts of bile duct ligated (BDL) rats was increased (»20%) com-
pared to controls. A hyperammonemic diet did not result in any further increase of AChE levels in the BDL
model, and no change was observed in hyperammonemic diet rats without liver disease. Portacaval shunted
rats which display increased levels of cerebral ammonia did not show any brain cholinergic abnormalities, con-
firming that high ammonia levels do not play a role in brain AChE changes. A selective increase of tetrameric
AChE, the major AChE speciesinvolvedin hydrolysis of acetylcholinein the brain, was detectedin both cirrhotic
humans and BDL rats. Histological examination of BDL and non-ligated rat brains shows that the subcellular
localization of both AChE and choline acetyltransferase, and thus the accessibility to their substrates, appears
unaltered by the pathological condition.The BDL-induced increase in AChE activity was not parallelled by an
increase in mRNA levels. Increased AChE in BDL cirrhotic rats leads to a pronounced decrease (»50^60%) in
the levels of acetylcholine. Finally, we demonstrate that the AChE inhibitor rivastigmine is able to improve
memory deficits in BDL rats.One week treatment with rivastigmine (0.6mg/kg; once a day, orally, for a week)
resulted in a 25% of inhibition in the enzymatic activity of AChE with no change in protein composition, as
assessed by sucrose density gradient fractionation and western blotting analysis. In conclusion, this study is the
first direct evidence of a cholinergic imbalance in the brain as a consequence of liver failure and points to the
possible role of the cholinergic system in the pathogenesis of hepatic encephalopathy.
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Alteration of normal brain function is a characteristic
complication of both acute and chronic liver failure and is
known as hepatic encephalopathy (HE). HE is characterized
by deficits in several neurotransmitter systems in the brain.
In particular, significant alterations in glutamatergic and
monoaminergic mechanisms, as well as endogenous opioid
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systems have been reported in both animal models of HE
and post-mortem brain tissue from patients with hepatic
liver disease (Butterworth, 1996; Felipo and Butterworth,
2002; Lozeva et al., 2004). However, thus far, there have
been few studies on alterations in the cholinergic system
during liver failure, with no significant conclusions (Rao
et al., 1994; Kabatnik et al., 1999; Jamal et al., 2007; Swapna
et al., 2007). In fact Butterworth and co-workers (Rao et al.,
1994) fail to demonstrate changes in the levels of
cholinergic enzymes in human and experimental portal-
systemic encephalopathy.
The cholinergic system, and specifically the neurotrans-
mitter acetylcholine (ACh), is involved in specific behav-
ioural responses and cognitive processes in both healthy
subjects and those with neurological dysfunction (Bartus
et al., 1982). Therapies designed to restore cholinergic
balance are based on the importance of cholinergic function
in cognition. The levels of ACh are continuously regulated
by choline acetyltransferase (ChAT), the enzyme which
synthesizes ACh and by acetylcholinesterase (AChE), which
rapidly degrades the neurotransmitter at cholinergic
synapses terminating synaptic transmission.
The present study investigates alterations in the levels of
both cholinergic enzymes, AChE and ChAT, in post-
mortem human brain tissue from patients deceased from
hepatic coma, as well as the levels of both enzymes and the
neurotransmitter ACh in cerebral cortex from several
animal models with and without liver failure. The ability
of rivastigmine, a widely prescribed reversible AChE
inhibitor, to revert cognitive deficits in bile duct ligated
(BDL) rats was also investigated.
Patients and Methods
Human brain samples
Small pieces ( 0.2g) of prefrontal cortex tissue, corresponding to
Brodmann area 9, were obtained post-mortem from four alcoholic
cirrhotic patients deceased from hepatic coma [3M/1F; average age
68 (60–86) years] and four control subjects free from any known
hepatic, neurologic and psychiatric disorders [2M/2F; average age
66 (60–73) years]. Studies in our laboratory have shown that for a
post-mortem interval472h, storage at  20 C or repeated cycles of
freeze-thawing caused degradation of AChE, which confounded
analysis. Thus, only samples which post-mortem delay 512h (for
all samples, with no differences between groups) were included.
Samples were stored at  80 C until analysis. These studies were
approved by the local ethics committee.
Animals and tissue preparation
All animal procedures were approved by the Universidad Miguel
Herna ´ndez’s Animal Care and Use Committee. Male Sprague-
Dawley rats weighing 250–300g at the times of surgery were used.
Several rat groups were used in this study: non-ligated (NL)
controls, BDL, BDL+hyperammonemic diet (BDL+HD), hyper-
ammonemic diet (HD) without liver failure and portacaval
shunted (PCS) rats.
Liver injury in BDL was induced by common bile duct-ligation as
previously described (Garc´ ıa-Ayllo ´n et al., 2006; Jover et al., 2006).
In NL controls, a midline incision was performed without BDL.
Hyperammonemia was induced in HD and BDL+HD rats by
feeding with a diet containing ammonium for 1 week until sacrifice
(Azor´ ın et al., 1989; Jover et al., 2006). BDL+HD rats were given the
ammonium diet the third week after the BDL. An additional control
group was included, sham pair-fed (PF) rats with equal control
diet consumption as that of the ammonium-containing diet eaten by
HD rats.
For behavioural tests, sham and BDL subgroups were treated
with the cholinesterase inhibitor rivastigmine (0.6mg/kg; Exelon,
Novartis Farmace ´utica S.A., Spain) or vehicle (saline), both
administered 2 weeks after BDL, once a day, orally, for a week.
Thus, all BDL rats were sacrificed 3 weeks after surgery, brains
removed and cerebral cortices dissected and stored at  80 C. In
PCS rats, portacaval anastomosis was performed according to Lee
and Fisher (1961). Rats were sacrificed 4 weeks after the surgery.
Brain homogenization and extraction
Approximately 0.2g of human prefrontal cortex and rat cortices
were homogenized (10% w/v) in ice-cold Tris–saline buffer
(50mM Tris–HCl, 1MNaCl and 50mMMgCl2, pH 7.4) supple-
mented with a cocktail of proteinase inhibitors (Garc´ ıa-Ayllo ´n
et al., 2006). The homogenates were centrifuged at 100000 ga t
4 C for 1h to recover a salt soluble fraction. The pellets were
re-extracted with an equal volume of Tris–saline buffer containing
1% (w/v) Triton X-100, and the suspension was centrifuged at
100000 ga t4  C for 1h to recover a detergent soluble fraction,
rich in membrane-bound enzyme. This method of extraction
allows greater extraction of total AChE activity (Sberna et al.,
1998). For the assay of enzyme activities equal volumes of salt and
detergent supernatants were combined.
Enzyme assays and protein determination
A modified microassay version of the Ellman method was used to
measure AChE and the structurally related butyrylcholinesterase
(BuChE) (Sberna et al., 1998; Garc´ ıa-Ayllo ´n et al., 2006). ChAT
was assayed by the procedure established by Fonnum (Sberna
et al., 1998). Protein concentrations were determined using the
bicinchoninic acid method (Pierce, Rockford, IL, USA).
Determination of ammonia
Ammonia was measured in plasma and cerebral cortex. Briefly,
blood (150ml) was taken from the tail vein in the morning, 21
days after surgery (or 28 days for PCS rats). The cerebral cortex
was homogenized as previously described (Jover et al., 2006) and
both blood and cortical extracts deproteinized (Jover et al., 2006).
Ammonia was measured in the neutralized supernatants by
fluorimetry (Fluoroskan Ascent Labsystems, Helsinki, Finland).
Sedimentation analysis of AChE molecular forms
AChE species were analysed by ultracentrifugation on a contin-
uous sucrose gradient (5–20% w/v) containing 0.5% (w/v) Triton
X-100, as previously described (Sberna et al., 1998). The AChE
present in brain is mainly distributed as tetramers (G4) and light
globular species (dimers, G2; monomers, G1). Peaks associated
with the major forms, were identified and the relative contribution
of each molecular form of AChE was also calculated.
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AChE variants were detected by immunoblotting. Briefly, rat brain
extracts (30mg) were resolved under reducing conditions by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on 10% polyacrylamide slab gels. After electrophoresis,
proteins were blotted onto nitrocellulose membranes, blocked with
5% non-fat milk and incubated overnight with a goat anti-AChE
polyclonal antibody (E-19, Santa Cruz Biotechnology, Santa Cruz,
CA). The nitrocellulose membrane strips were then incubated with
a horseradish peroxidase (HRP)-conjugated donkey anti-goat IgG
secondary antibody (Santa Cruz Biotechnology) and immunor-
eactive AChE was detected using the ECL-Plus kit (Amersham Life
Science, Arlington Heights, IL, USA) in a Luminescent Image
Analyzer LAS-1000 Plus (Fujifilm, Stamford, CT, USA). Molecular
weight markers were used to determine protein size (Sigma-
Aldrich Co., St Louis, MO, USA). For semi-quantitative analysis,
the intensity of AChE bands was measured with Science Lab
Image Gauge v4.0 software provided by Fujifilm.
AChE histochemistry and immunocytochemistry
Animals were perfused through the heart with 0.1M phosphate
buffer (PB), pH 7.4, followed by 4% paraformaldehyde in PB
containing 1% CaCl2. The brain was then removed and immersed
in the same fixative overnight. The brains were serially sectioned
at 50mm in a sliding microtome (Microm, Heidelberg, Germany)
coupled to a freezing unit. AChE staining was examined by
immunohistochemical analysis with the anti-AChE antibody E-19
(1:100 dilution). Similar sections were also incubated with the
polyclonal anti-ChAT antibody (1:200 dilution; Chemicon
International, Temecula, CA, USA).
RNA isolation and analysis of AChE and ChAT
transcripts by QRT-PCR
Total RNA from NL and BDL rat brain was isolated using
TRIzol Reagent in the PureLink
TM Micro-to-Midi Total RNA
Purification System (Invitrogen
TM Life Technologies, Foster City,
CA, USA) according to the manufacturer’s instructions. cDNAs
were synthesized using SuperScript
TM III Reverse Transcriptase
(Invitrogen
TM Life Technologies) according to the manufacturer’s
instructions using 5mg of total RNA and oligo (dT)12-18.
Quantitative reverse transcription-polymerase chain reaction
(QRT-PCR) amplification was performed using a StepOne
TM
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) with Power SYBR Green PCR Master Mix according to the
manufacturer’s instructions (see primer sequence in Table 1).
Transcript levels for AChE (R and T transcripts) and two splice
forms of ChAT, the cholinergic (cChAT) and the peripheral
(pChAT) were calculated using the relative standard curve method
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Microdialysis and perfusate analysis of ACh
On day 18 after the BDL surgery, a microdialysis guide (CMA/12
guide cannula; CMA/Microdialysis AB, Solna, Sweden) was
implanted 3mm above the coordinates in the prefrontal cortex
(AP 3.7, ML  0.8, DV  1.0, from brain surface). Three days later
a 3mm long microdialysis probe (CMA/12, Solna, Sweden) was
lowered and perfused (3ml/min) with artificial cerebrospinal fluid
(145mMNaCl, 3.0mMKCl, 2.26mMCaCl2, 2mM phosphate, pH
7.4) containing 2mM of the cholinesterase inhibitor neostigmine
chloride (Damsma et al., 1985; Chang et al., 2006). As AChE is
very efficient at removing extracellular ACh, obscuring differences
in ACh release, inclusion of the AChE inhibitor in the micro-
dialysis perfusate was necessary to observe functional changes in
ACh release (Rao et al., 1994). As extracellular ACh levels in the
prefrontal cortex are influenced by circadian rhythm (Mitsushima
et al., 1996), time of sampling was controlled and limited to a
short period during the light phase (between 11:00 AM and 2:00
PM). Following a stabilization period of at least 2h, samples were
collected every 20min. ACh in the perfusate was measured using
high-performance liquid chromatography with electrochemical
detection, as previously described (Damsma et al., 1985). ACh
values presented are uncorrected for probe recovery (32% of
recovery) and expressed in nanomolars.
Behaviour studies
Behavioural tests were performed to analyse memory and learning
functions (active avoidance and object recognition tests) and
motor coordination (rotarod). The tests were performed 3h after
the final administration of rivastigmine.
Active avoidance
The active avoidance task is designed to test the ability of the rats
to avoid an aversive event by first learning to perform a specific
behaviour in response to a stimulus cue. The test was performed
in one single day and consisted of 50 trials per animal, as
previously described (Aguilar et al., 2000).
Object recognition test
This test exploits the tendency of rats to preferentially explore novel
elements of their environment. Thus, when a rat is presented with
both a novel and recently presented familiar object, it will spend
significantly more time exploring the novel object. The familiar
object was presented in a previous training session 4h before the
test. The percentage of time exploring the non-familiar object in
the training session over total exploration time (exploration time of
the familiar plus the non-familiar objects) was represented.
Table 1 Primer design and optimization for QRT-PCR
Primer Sequence Optimun
concentration
(nM)
Amplicon
lengh (nt)
GAPDH
forward TGGGAAGCTGGTCATCAAC 100 78
reverse GCATCACCCCATTTGATGT 100
AChE-T
forward CAGCAATACGTGAGCCTGAA 100 123
reverse CTCGTCCAGCGTGTCTGT 100
AChE-R
forward CTCAGCGCCACAGGTAGG 200 76
reverse TCTCTCCCGTCCTTCCAAC 200
cChAT
forward GGTGTGGTGTGTGAGCATTC 200 167
reverse TGGGTTTCTGGGGAACATT 200
pChAT
forward CTGCTGGACAGGATGACAAG 200 104
reverse TGGGTTTCTGGGGAACATT 200
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The rotarod test assesses the ability of rats to stay on a rotating
drum to evaluate motor coordination functions. An accelerating
rotarod was used (Ugo Basile, Comerio, Italy). Two consecutive
days before testing, each rat was placed on the rotarod which was
switched off for 3min. The rotarod speed was then increased from
4 to 40r.p.m. over 300s. The time at which each animal fell off
the rungs was recorded, with a maximum cut-off of 600s.
Statistical analysis
Measurements are expressed as means SEM. Data were analysed
by a Student’s t-test or by an one-way analysis of variance
followed by a post hoc Tukey–Kramer test for multiple
comparisons between groups. Statistical significance was desig-
nated as P50.05.
Results
Assay of AChE activity revealed that frontal cortex extracts
from HE patients had higher enzyme activity (33%
increment; P=0.02) compared to non-cirrhotic (NC)
controls, while ChAT activity remains unaltered (Fig. 1A
and B). The specificity of the changes in AChE activity was
supported by the observation that the activity of the related
enzyme BuChE, in extracts from cirrhotic individuals, was
not different from that in control subjects (Fig. 1C).
Additionally, as AChE is expressed as several molecular
forms (Massoulie ´ et al., 1993; Taylor and Radic, 1994),
we determined whether the observed increase in AChE
activity in cirrhotic subjects was due to an increase of a
particular molecular form. Brain frontal cortex supernatants
were fractionated on sucrose density gradients to separate
AChE species. In HE samples, there was a small increase in
the major AChE tetrameric form peak (P=0.036) with
respect to control samples (Fig. 1D).
Next, we examined the levels of these enzymes in rat
brain from several pathological models (Fig. 2). In
agreement with the human data, AChE activity in cortical
extracts of cirrhotic BDL rats was increased ( 20%
increase; P=0.004) compared to NL controls, while the
levels of ChAT and BuChE remain unaltered (Fig. 2A–C).
Activity levels were similar in BDL and BDL + HD rats,
while neither change was found in HD rats without liver
disease fed with an ammonium-containing diet for 1 week
(Fig. 2A–C), nor in sham PF rats (not shown). In good
agreement with previous observations (Huang et al., 2004;
Jover et al., 2006), the trend was for plasma ammonia levels
to increase in BDL rats, but only BDL+HD and HD rats
were hyperammonemic (Fig. 2D). More interestingly, only
BDL+HD rats showed increased ammonia in the cerebral
cortex (Fig. 2E). The lack of correlation between AChE
alterations and ammonia levels was corroborated in the
PCS group. After 4 weeks of portacaval anastomosis, these
rats’ large increases in ammonia levels were observed in
both plasma and cortex (Fig. 2D and E), while cholinergic
markers were unaffected (Fig. 2A–D).
The major AChE tetrameric form was significantly
increased in the cirrhotic rat cortices from BDL rats
compared to controls (P=0.039; Fig. 3). A similar trend
was observed for BDL+HD rats (Fig. 3).
We also assessed whether the subcellular location of both,
AChE and ChAT were modified by the BDL condition
(Fig. 4). Immunoreactivity to AChE and ChAT showed
consistent and similar expression in both experimental and
control animals. While strong immunoreactive signal was
observed in the perinuclear area of pyramidal cells in
frontal cortex layer V, a weak reaction was localized in the
cytoplasm of these cells, staining within basal and apical
dendrites. Some small cells around the pyramidal neurons
also show perinuclear labelling with very weak cellular
signal. No difference observed in the localization and
intensity of the AChE and ChAT immunoreactivity in all
the analysed coronal sections of control NL (n=3), BDL
(n=3) and BDL+HD (n=3) rats.
Some of the molecular heterogeneity of AChE derives
from alternative RNA splicing, generating different poly-
peptide encoding transcripts with the same catalytic
domain, but distinct C-terminal peptides that determine
the ability of the molecule to form oligomers (Massoulie ´
et al., 1993; Taylor and Radic, 1994; Grisaru et al., 1999).
To determine if AChE expression is altered in BDL rats, we
performed QRT-PCR analysis of the AChE mRNA.
Fig.1 (A)A C h E ,( B)C h A Ta n d( C) BuChE activity levels in frontal
cortex extracts from NC controls (n=4)andpat ientswithH E
(n=4) .( D) Representative profiles of AChE molecular forms
(G4=tetramers; G1+G 2=monomers+dimers) and the activity of
each AChE molecular form are also shown.Values are
means SEM.
 P50.05.
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mammalian brain that encodes subunits which produce
monomeric and tetrameric forms, was unaltered in cortices
from BDL rats compared to controls (Fig. 5A). Similarly,
levels of the R-transcript which encodes monomeric soluble
subunits and is normally present at low levels in the
mammalian brain (Kaufer et al., 1998) did not vary in BDL
animals compared to controls (Fig. 5A). QRT-PCR analysis
was used to determine the mRNA levels for both the
conventional cholinergic ChAT transcript, the major variant
found in both central and peripheral neurons [protein
product is called ChAT of the common type (cChAT)], and
also transcriptional levels for the minor splice variant
[protein product designated ChAT of a peripheral type
(pChAT)], which is predominantly localized in peripheral
neurons (Tooyama and Kimura, 2000). As expected for the
unmodified ChAT enzyme activity, the levels of both
cChAT and pChAT were unaltered in cortices from BDL
rats compared to NL controls (Fig. 5A).
As AChE is present as both active and inactive subunits
(Rotundo, 1988; Chatel et al., 1993; Garc´ ıa-Ayllo ´n et al., 2006,
2007), we performed immunoblotting to assess whether
altered activity levels correlated with increases in the total
pool of AChE protein. Rat cortical extracts were analysed by
SDS–PAGE under fully reducing conditions, followed by
western blotting using the anti-AChE antibody E-19. This
polyclonal antibody was raised against a peptide mapping to
the amino terminus of AChE,common toall AChEforms and
thus presumably detects all species, including inactive
Fig. 2 Levels of (A)A C h E ,( B)C h A Ta n d( C) BuChE in cortical extracts from sham NL controls, BDL rats without and with HD
(BDL+HD), HD without liver disease fed with an ammonium-containing diet for1week and PCS rats. (D)P l a s m aa n d( E) cerebral
ammonia levels were also determined for each rat group.Values are means SEM.
 P50.05, significantly different from NL group; there
were no statistically significant differences between BDL and BDL+HD groups (at least n=6foreachg roup ) .
Fig. 3 Representative profiles of AChE molecular forms
(G4=tetramers; G1+G 2=monomers and dimers) and the activity
of each molecular AChE form, for sham NL controls, BDL rats and
BDL rats with HD (BDL+HD) (n=6 for each group).Values are
means SEM.
 P50.05, significantly different from NL group.
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major bands of  77, 70 and 60kDa (Fig. 5B). Neither the
intensity of the individual bands nor their relative banding
pattern was altered in BDL rats compared to controls.
In an attempt to assign immunopositive AChE bands to
specific AChE species, immunoblots were performed for the
G4 and G1+G 2 peaks from sucrose density gradients
(Fig. 5C). In both NL and BDL rats, the majority of the G4
peakwas70kDa,whileblotsofmaterialfromtheG1+G 2peak
showed all three AChE bands, similar to total extracts. There
was no correlation between increased G4 cortical AChE
activity in BDL with immunoreactivity as much of the AChE
immunoreactivity was associated with unaltered protein that
was present in the G1+G 2 peak and may correspond to both
active and inactive subunits (Garc´ ıa-Ayllo ´n et al., 2007).
Complementary to the imbalance in cholinergic enzymes
and increased catalytic AChE activity in cerebral cortex
extracts, extracellular ACh levels obtained during in vivo
Fig. 4 AChE and ChAT detection in the cerebral cortex of control and experimental rats. (A^I) AChE immunoreactivity in brain frontal
cortex in normal (NL) rats (A^C), BDL rats, (D^F) and BDL+HD rats (G^I).The immunopositive staining is mainly localized in the
perinuclear area of layer V pyramidal neurons in both control and experimental samples. Inserts show the progressive higher power pic-
tures in the localized areas for each rat model. Scale bar: 250 microns in (A), (D)a n d( G); 100 microns in (B), (E)a n d( H); and 30 microns
in (C), (F)a n d( I). (J^O) ChAT immunoreactivity of frontal cortex in normal (NL) rats (J and M), BDL rats (K and N) and BDL+HD rats
(L and O). Immunopositive staining is mainly localized in the perinuclear area of layer V pyramidal neurons in control and experimental
samples. Inserts show progressive higher power pictures in localized areas for each rat model. Scale bar: 250 microns in (J), (K)a n d( L); 100
microns in (M), (N)a n d( O). No significant staining was found in cortical superficial layers in pyramidal cells or interneurons, only apical
processes of pyramidal neurons could be followed from layer V. Not staining was observed in the white matter.
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BDL and a 66% decrease in BDL+HD rats compared to NL
rats (P50.001; Fig. 6). All microdialysis fractions were per-
formed with the addition of 2mM of the cholinesterase
inhibitor neostigmine in the perfused solution, which is
necessary to avoid degradation of ACh in the extracellular
space.
To assess potential behavioural changes, we performed an
active avoidance test in the animal models to analyse memory
and learning functions. Cirrhotic BDL and BDL+HD rats
were the only groups that demonstrated a decrease in the
number of attempts made to avoid foot shock compared to
control rats (P50.02; Fig. 7).
Fig. 5 Immunodetection of AChE subunits anddetection of AChE
andChATtranscriptsinbraincortex fromNL andBDLrats.(A)
RelativemRNAlevelsof the transcriptsforAChE(TandR;labelled
AChE-TandAChE-Rinthefigure)andChAT(cholinergic andper-
ipheral;cChATandpChAT)wereanalysedbyQRT-PCR.Valueswere
calculatedusingrelativestandardcurvesandnormalizedtoGAPDH
controlfromthesamecDNApreparations.Specifityof thePCR
productswasconfirmedbydissociationcurveanalysis.(B)Th r ee
major AChEbands of 77,70and60kDawereidentifiedwith the
antibodyE-19inNL andBDLbraincorticalextracts(equivalent
amounts ofproteinwereloadedin eachlane).None of themajor
AChEimmunopositivebandswerealteredwhencomparingNL and
BDL animals. (C) Representativeimmunoblotofindividual G4and
G1+G 2AChEpeak-fractionsseparatedbysucrosegradientcentri-
fugationfromNLandBDLbraincorticalextracts(equivalentvolume
ofG4andG1+G 2AChEpeak-fractionswereloadedineachlane).
Fig. 6 Levels of ACh in cortical extracts from sham NL controls,
and BDL rats without and with HD (BDL+HD). ACh values are
uncorrected for probe recovery (32% of recovery) and represent
means SEM.
 P50 . 0 5 ,s i g n i f i c a n t l yd i f f e r e n tf r o mN Lg r o u p ;t h e r e
were no statistically significant differences between BDL
and BDL+HD groups (n=6foreachg roup ) .
Fig. 7 Result of the active avoidance test in sham NL controls,
BDL rats, BDL rats+HD (BDL+HD), rats fed with a HD without
liver disease, and PCS rats.Only cirrhotic BDL and BDL+HD rats
showed a decrease in the number of attempts made to avoid the
f o o ts h o c ka sc o m p a r e dw i t hN Lc o n t r o l s(
 P50.02).Values are
means SEM (at least n=6foreachg roup ) .
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learn the active avoidance task was dependent on
cholinergic imbalance, which in turn leads to memory
deficits. Thus, we tested whether rivastigmine, a widely
prescribed reversible AChE inhibitor, was able to improve
this deficit, and extended our analysis to include another
memory test, the object recognition test. In addition, motor
coordination of the rats was assessed using the rotarod. We
concentrated our analysis on the BDL group administered
rivastigmine 2 weeks after bile duct-ligation, once a day
(0.6mg/Kg daily), orally, for a week. AChE measurements
in frontal cortex extracts from rats sacrificed after
performing behaviour tests, demonstrated a 25% of
inhibition of AChE enzymatic activity, similar to previous
observations (Amenta et al., 2006). Up-regulation of AChE
in response to chronic inhibition is well recognized
(Chiappa et al., 1995; Friedman et al., 1996; Keller et al.,
2001). As this may interfere with the therapeutic response,
we determined whether rivastigmine treatment modified
protein composition by fractionating the different AChE
molecular forms on sucrose density gradients. These
analyses revealed that peaks corresponding to the major
AChE tetramers and to the minor light forms were
decreased similarly in both rivastigmine-treated BDL and
control animals (Fig. 8A). Rivastigmine can also affect
AChE activity, thus we extended our examination to
include western blotting analysis. Neither the intensity of
the individual bands nor their relative banding pattern was
altered in rivastigmine-treated rats compared to vehicle-
treated controls (Fig. 8B).
Interestingly, rivastigmine restored learning abilities in
BDL rats tested for active avoidance (P=0.003; Fig. 9A).
However, treatment with rivastigmine demonstrated trends
to negatively affect memory performance in control rats
tested for object recognition, as compared with sham-vehicle
treated rats (P=0.16; Fig. 9B). Despite this tendency, BDL-
rivastigmine treated rats displayed restored learning abilities
compared with BDL-vehicle treated rats (P=0.04; Fig. 6B).
Rats with BDL have previously been shown to have decreased
motor activities (Chan et al., 2004; Jover et al., 2006),
correlating with some of the typical signs found in patients
with HE developed during chronic liver disease. In the
current study, the BDL rats demonstrated mild impairment
Fig. 8 Change in levels of brain AChE species in response to
rivastigmine or vehicle treatment in NL and BDL rats (A)r e p r e -
sentative profiles of AChE molecular forms. (B) Immunodetection
of AChE variants analysed by western blot with the anti-N-term-
inal AChE antibody N-19 (equivalent amounts of protein were
loaded in each lane). None of the major AChE immunopositive
bands were altered when comparing rivastigmine and vehicle
treated animals.
Fig. 9 Effect of the AChE inhibitor rivastigmine on conditioned stimuli response (avoidances) in the active avoidance test (A), the object
recognition test (B) and on the rotarod motor coordination test (C), for NL and BDL rats (n=10 for each subgroup).
 P50.05 for a dif-
ference between NL-vehicle and BDL-vehicle rats;
yP50.05 for a difference between BDL-vehicle and BDL-rivastigmine treated rats. Note
that BDL-rivastigmine treated rats show differences in the number of avoidances and in the percentage of time exploring the non-familiar
object, as compared with BDL-vehicle rats. No differences in the time on the rotarod were observed between BDL-rivastigmine treated
rats and BDL-vehicle rats.
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rotarod (P=0.02; Fig. 9C). This was not reversed by
rivastigmine treatment signifying the specificity of its effects
in learning abilities.
Discussion
This is the first study that describes an alteration in AChE
activity in human and rat brain cortex as a consequence of
liver failure. In the animal model, increased AChE leads to
a pronounced decrease in the levels of the neurotransmitter
ACh which plays a critical role in cognitive function. Thus,
our data suggests that impairment of the brain cholinergic
system induced by liver disease may be associated with
failure in learning and memory functions. Interestingly, it
has been demonstrated that disrupting the cholinergic
balance itself by transgenic expression of AChE in mice
causes progressive decline (Beeri et al., 1995).
Hyperammonemia is considered one of the main factors
responsible for HE-neurological alterations (Felipo and
Butterworth, 2002). While the contribution of hyperam-
monemia to brain cholinergic disturbances cannot be
completely ruled out, our data suggests that high ammonia
levels are not a precipitant factor in brain AChE changes.
There is no correlation between increased ammonia levels
and increased brain AChE activity level changes in the
animal models examined. BDL rats, an animal model of
liver failure, showed the same degree of alteration in both,
AChE and ACh levels, as the BDL+HD animals, a model
of liver failure and HE. Nonetheless, only BDL+HD rats
showed increased ammonia in the cerebral cortex. Neither
HD fed nor PCS rats (which display a large increase in
brain ammonia) demonstrated changes in the levels of
cholinergic markers. Therefore, only cirrhotic animals,
independent of the degree of hyperammonemia, mimic
the increase in brain AChE levels in human alcoholic
cirrhotic subjects.
It has recently been reported that ethanol can cause
cholinergic imbalance (Jamal et al., 2007). Moreover
alterations in AChE kinetic properties have been described
in thioacetamide-induced HE (Swapna et al., 2007).
Interestingly, significant AChE increases after acute ethanol
exposure have been demonstrated in the zebrafish brain,
whereas ethanol in vitro did not alter enzymatic activity
(Rico et al., 2007). Further studies addressing the possibility
that other precipitant factors, such as manganese (Krieger
et al., 1995), may contribute to cholinergic imbalance
symptoms are warranted as it has been suggested that
manganese may modulate cholinergic systems, including
affecting AChE activity (Finkelstein et al., 2007). Moreover,
we have recently showed in BDL rats a pronounced
decrease in liver and plasma AChE levels, with selective
loss of the G4 specie (Garc´ ıa-Ayllo ´n et al., 2006). The
decrease of serum G4 levels in BDL rats correlates with a
decrease of the tetrameric species in the cerebrospinal fluid
(unpublished observation). Thus, the possibility that overall
decreases in peripheral AChE activity in BDL rats may
influence cerebrospinal fluid contents and trigger a central
response, resulting in the accumulation of AChE in the
brain, also deserves consideration.
Alterations in AChE activity have not been previously
observed in brains of deceased cirrhotic patients, nor in
portacaval-shunted rats (Rao et al., 1994). Discrepancy
within human studies may be due to differences in protein
extraction protocols or handling/measurement of samples.
In the study by Rao et al. (1994) both extraction and assay
buffers were detergent-free; while homogenization of brain
without detergent releases AChE activity, most of the brain
AChE corresponds to amphiphilic species that requires
incubation with detergents, such as Triton X-100, for
optimized extraction and expression of full catalytic activity
(Massoulie ´ et al., 1993; Sa ´ez-Valero et al., 1993). Thus, we
believe that the use of detergent-free buffers by our
colleagues may have contributed to the divergent results.
We present evidence that in both, cirrhotic humans and
rats, increased AChE activity is associated with a parallel
increased in the major amphiphilic tetrameric molecular
form.
AChE is widely distributed within different brain regions
and is expressed as several molecular forms with a specific
pattern that is altered in many pathological processes
(Massoulie ´ et al., 1993). The different molecular forms of
AChE may thus reflect specific physiological functions of
the enzyme with different regulatory requirements. The
BDL-induced increase in G4, which is the major AChE form
in the brain, was not accompanied by a change in its
T-transcript. AChE levels are regulated at transcriptional,
post-transcriptional and post-translational levels, leading to
complex expression patterns which are modulated by
physiological and pathological conditions through mecha-
nisms that are not fully understood. In previous studies, we
have demonstrated by immunoblotting that both active and
inactive AChE species can be detected (Garc´ ıa-Ayllo ´n et al.,
2006, 2007). In this study, neither the intensity of the
individual bands nor their relative banding patterns were
altered by the BDL conditions. The immunoblotting assays
revealed a complex AChE banding pattern with no direct
relationship between specific molecular forms and enzy-
matic activity. It is thus not possible to correlate increased
G4 activity with altered immunoreactivity.
While the different molecular forms of AChE may have
specific physiological functions (Massoulie ´ et al., 1993;
Taylor and Radic, 1994), within the brain, hydrolysis of
ACh is probably mediated through the G4 plasma
membrane-bound form (Lazar and Vigny, 1980; Taylor
et al., 1981). Immunohistochemical examination of BDL
and NL rat brains show that the subcellular localization of
both, AChE and ChAT, and thus the accessibility to their
substrates, appears unaltered by the pathological condition.
Therefore, the excessive levels of the cholinergic G4 AChE
in the brain of cirrhotic subjects may have direct
physiological consequences causing a decrease of
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cholinesterase activities present in the brain such as
BuChE may also contribute to ACh hydrolysis. However,
the regulation of each AChE form and of the BuChE is
probably controlled by different mechanisms (Garc´ ıa-Ayllo ´n
et al., 2007). Our data indicates that only the tetrameric
AChE form, the ‘true’ cholinergic species, is affected during
liver failure.
Cholinesterase inhibitors are widely used for treating
cholinergic dysfunction associated with dementia (Giacobini,
2002). Rivastigmine, has an advantage over other cholines-
terase inhibitors as it is metabolized to an inactive metabolite
at the site of action, bypassing hepatic metabolic pathways
and as a result has unaltered bioavailability in subjects with
renal or hepatic impairment. We found sustained inhibition
of AChE enzymatic activity in the rat brain after 1 week of
rivastigmine treatment. Despite the conserved AChE catalytic
domain, in vitro studies have shown that some AChE
inhibitors display differential selectivity for different AChE
species (Ogane et al., 1992; Zhao and Tang, 2002; Rakonczay,
2003). Rats treated with rivastigmine for 1 week demonstrate
similar inhibition of both tetrameric and light AChE species.
This was not associated with significant changes in AChE
protein composition. In addition, AChE up-regulation has
been demonstrated in reaction to chronic inhibition; rats
administered with the organophosphate insecticide chlorpyr-
ifos show a dose-dependent decrease in the activity of brain
AChE, while immunoreactive AChE protein increased after 3
weeks of treatmen with the higher doses (Chiappa et al.,
1995). In our treatment conditions, and using SDS–PAGE/
western blotting analysis, stable levels of AChE protein were
observed, discarding early up-regulation responses of the
AChE protein within 1 week of rivastigmine treatment. More
interestingly, we demonstrate the ability of this cholinesterase
inhibitor to improve the memory deficit observed in
cirrhotic rats.
The majority of HE patients are usually treated for their
hepatic manifestations rather than their neuropsychiatric
symptoms and therefore represent an untreated ‘psychiatric’
population. It has been suggested in a case report that HE
may trigger a central anticholinergic syndrome that can be
treated with the AChE inhibitor physostigmine (Kabatnik
et al., 1999). Therapies based on the use of cholinesterase
inhibitors for treating neurological manifestations asso-
ciated with liver diseases thus deserve further consideration.
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